Background: The antihypertensive activity of beta-blockers generally increases during the
first 6 to 8 weeks of treatment; however, no study has systematically assessed whether blood …

Nebivolol is a novel, β1-adrenergic receptor blocker with vasodilatory properties mediated
through the activation of the l-arginine/nitric oxide pathway. Short-term randomized clinical …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

In order to evaluate the efficacy and tolerability of nebivolol during long term treatment of
outpatients with hypertension, 6 open multicentre studies are being carried out in 5 different …

Background: In clinical studies, nebivolol at doses of 2.5 to 40 mg once daily was associated
with significant decreases in systolic blood pressure (SBP) and diastolic BP (DBP) in …

Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …

Nebivolol has been adequately tested in clinical efficacy trials of patients with mild
hypertension. Clinical efficacy trials or their metaanalyses did not accurately predict the …

2. Results During nebivolol treatment, significant (p< 0.000 I) decreases occurred in systolic
and diastolic blood pressure and heart rate. In the supine position, systolic blood pressure …

This study assessed blood pressure (BP) reductions and response rates following addition
of nebivolol to ongoing antihypertensive therapy in patients with uncontrolled stage I–II …

Abstract β-Adrenergic receptor blockers (β-blockers) are well-known useful and cost-
effective drugs for managing hypertensive patients with coronary heart disease, stroke, and …